All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
While it awaits results from a confirmatory trial with hereditary angioedema drug DX-88, Cambridge, Mass.-based Dyax Corp. picked up another partner for its antibody platform, signing Sanofi-Aventis in a potential $500 million deal. (BioWorld Today)